GESTIÓN PARA UNA EDUCACIÓN DE CALIDAD EN UNA INSTITUCIÓN EDUCATIVA PERUANA

La investigación abordó el enfoque cuantitativo, con el objetivo de demostrar la gestión del Consejo Municipal del distrito de San Juan de Lurigancho en la educación y la gestión de “educación vivencial” de los docentes de la Coordinación de Ciencias Sociales para una educación de calidad de los estudiantes de la Institución Educativa N° 157 CAP. FAP. “José Abelardo Quiñones” del distrito de San Juan de Lurigancho año 2017 Lima - Perú. La muestra fue 235 estudiantes de una población de 590 estudiantes, colegio mixto, con resultados significativos en el caso de la gestión del consejo municipal en el desarrollo de la educación, 195 estudiantes afirmaron no contar con el apoyo del consejo municipal para la mejora de la calidad educativa, asimismo del total de 32 profesores 30; profesores afirman no contar con el apoyo del Consejo  Municipal del distrito, del mismo modo; de una población de 160 padres de familia 145 padres de familia afirmaron no contar con la ayuda del Consejo Municipal en la educación de sus hijos. En cuanto a la Educación Vivencial que desarrolla la coordinación de ciencias sociales; 215 estudiantes afirmaron mejor estrategia de enriquecer conocimientos con educación vivencial realizada. Asimismo 205 estudiantes manifestaron, que hay una educación de calidad con el desarrollo de los proyectos de educación experiencial realizada por la coordinación de Ciencias Sociales a Lomas de Lachay, Caral y los centros históricos de Lima

Percepción de contaminación acústica y el aprendizaje de los estudiantes de una institución educativa andina: Perception of noise pollution and student learning in an Andean educational institution

Estudio realizado en estudiantes de una institución educativa de Huancavelica, ubicada en la región andina del Perú. Existe una percepción importante de la contaminación acústica y su repercusión en el proceso de aprendizaje de los estudiantes

Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19 : a meta-analysis

IMPORTANCE Clinical trials assessing the efficacy of IL-6 antagonists in patients hospitalized for COVID-19 have variously reported benefit, no effect, and harm. OBJECTIVE To estimate the association between administration of IL-6 antagonists compared with usual care or placebo and 28-day all-cause mortality and other outcomes. DATA SOURCES Trials were identified through systematic searches of electronic databases between October 2020 and January 2021. Searches were not restricted by trial status or language. Additional trials were identified through contact with experts. STUDY SELECTION Eligible trials randomly assigned patients hospitalized for COVID-19 to a group in whom IL-6 antagonists were administered and to a group in whom neither IL-6 antagonists nor any other immunomodulators except corticosteroids were administered. Among 72 potentially eligible trials, 27 (37.5%) met study selection criteria. DATA EXTRACTION AND SYNTHESIS In this prospectivemeta-analysis, risk of biaswas assessed using the Cochrane Risk of Bias Assessment Tool. Inconsistency among trial results was assessed using the I-2 statistic. The primary analysis was an inverse variance-weighted fixed-effects meta-analysis of odds ratios (ORs) for 28-day all-cause mortality. MAIN OUTCOMES AND MEASURES The primary outcome measurewas all-cause mortality at 28 days after randomization. There were 9 secondary outcomes including progression to invasive mechanical ventilation or death and risk of secondary infection by 28 days. RESULTS A total of 10 930 patients (median age, 61 years [range of medians, 52-68 years]; 3560 [33%] were women) participating in 27 trials were included. By 28 days, there were 1407 deaths among 6449 patients randomized to IL-6 antagonists and 1158 deaths among 4481 patients randomized to usual care or placebo (summary OR, 0.86 [95% CI, 0.79-0.95]; P =.003 based on a fixed-effects meta-analysis). This corresponds to an absolute mortality risk of 22% for IL-6 antagonists compared with an assumed mortality risk of 25% for usual care or placebo. The corresponding summary ORs were 0.83 (95% CI, 0.74-0.92; P <.001) for tocilizumab and 1.08 (95% CI, 0.86-1.36; P =.52) for sarilumab. The summary ORs for the association with mortality compared with usual care or placebo in those receiving corticosteroids were 0.77 (95% CI, 0.68-0.87) for tocilizumab and 0.92 (95% CI, 0.61-1.38) for sarilumab. The ORs for the association with progression to invasive mechanical ventilation or death, compared with usual care or placebo, were 0.77 (95% CI, 0.70-0.85) for all IL-6 antagonists, 0.74 (95% CI, 0.66-0.82) for tocilizumab, and 1.00 (95% CI, 0.74-1.34) for sarilumab. Secondary infections by 28 days occurred in 21.9% of patients treated with IL-6 antagonists vs 17.6% of patients treated with usual care or placebo (OR accounting for trial sample sizes, 0.99; 95% CI, 0.85-1.16). CONCLUSIONS AND RELEVANCE In this prospectivemeta-analysis of clinical trials of patients hospitalized for COVID-19, administration of IL-6 antagonists, compared with usual care or placebo, was associated with lower 28-day all-cause mortality